God morgen. Ja nogle firmaer er ramt hårdere end andre af de høje renter og Genmab er sluppet billigt i.f.r mange andre. US fonde har sikkert solgt ud i Danske aktier.

]]>https://dev.proinvestor.com/forum/topic/399177/genmab-oktober-2023RSS for NodeSun, 07 Jun 2026 21:39:58 GMTSun, 01 Oct 2023 04:34:38 GMT60"knock your socks off" kind of potent.

]]>https://dev.proinvestor.com/forum/post/7668073https://dev.proinvestor.com/forum/post/7668073Tue, 31 Oct 2023 21:41:34 GMTKan huske at Plesner var svært nervøs for om første dose af dara i et menneske var for stærk. Så det må dæleme være potent.

]]>https://dev.proinvestor.com/forum/post/7668070https://dev.proinvestor.com/forum/post/7668070Tue, 31 Oct 2023 18:55:26 GMTnemlig og min største tro på, at den går hjem

]]>https://dev.proinvestor.com/forum/post/7668072https://dev.proinvestor.com/forum/post/7668072Tue, 31 Oct 2023 18:14:28 GMThttps://haematologisktidsskrift.dk/sygdomme/myeloma/996-mere-effektiv-version-af-daratumumab-tyder-lovende-i-tidlige-forsog.html

]]>https://dev.proinvestor.com/forum/post/7668069https://dev.proinvestor.com/forum/post/7668069Tue, 31 Oct 2023 18:12:40 GMTVi har Plesners udtalelse fra april sidste år: “ Efter vi påbegyndte studiet for et år siden har vi nu formået at nå den maksimale påtænkte dosis uden nogen alvorlige bivirkninger, hvilket er det primære formål for studiets fase I, og det er meget positivt,” siger han.

]]>https://dev.proinvestor.com/forum/post/7668074https://dev.proinvestor.com/forum/post/7668074Tue, 31 Oct 2023 18:11:36 GMTDer er denne artikel fra juni, men resultater fra klinikken holder de tæt til kroppen: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00228-1/fulltext

]]>https://dev.proinvestor.com/forum/post/7668065https://dev.proinvestor.com/forum/post/7668065Tue, 31 Oct 2023 18:04:01 GMTDet lyder godt nok potent. Men har vi ikke fået andre indikationer siden?

]]>https://dev.proinvestor.com/forum/post/7668067https://dev.proinvestor.com/forum/post/7668067Tue, 31 Oct 2023 17:18:31 GMTJeg fandt lige følgende fra Handelsbanken dateret oktober 2022 angående Hexabody CD38 »For indeværende indikerer de prækliniske data for Hexabody-CD38, at antistoffet er ti gange mere potent end Darzalex, om end sikkerhedsprofilen endnu ikke er bekræftet. Endelige forsøgsdata vil blive offentliggjort i de kommende 12-18 måneder,« skriver Handelsbanken i sit morgenbrev. Har vi ikke hørt yderligere det seneste år.?

]]>https://dev.proinvestor.com/forum/post/7668068https://dev.proinvestor.com/forum/post/7668068Tue, 31 Oct 2023 17:17:29 GMThttps://www.irishtimes.com/business/2023/10/25/irish-jobs-to-go-as-amgen-cuts-350-horizon-employees-after-takeover/ Detvar så kun ca 20% de fyrede. Men lidt omstilling vil koste på omsætningen kortvarigt må man vel forvente. Spændende hvad den store organisation kan gøre ved Tapezza.

]]>https://dev.proinvestor.com/forum/post/7668061https://dev.proinvestor.com/forum/post/7668061Tue, 31 Oct 2023 16:52:43 GMTAmgen fyrede vel de fleste af Horizons ansatte for nylig. Så forventningerne skal ikke sættes for højt. Men mon ikke de kan komme ud over stepperne i 2024 og få udbredt Tapezza i hele verden med $5 bn, som endegyldigt salgsmål/peaksales.

]]>https://dev.proinvestor.com/forum/post/7668062https://dev.proinvestor.com/forum/post/7668062Tue, 31 Oct 2023 16:04:05 GMTWorse than expected Darzalex and Tapezza numbers recently. Do we have a little problem in the coming quarters?

]]>https://dev.proinvestor.com/forum/post/7668063https://dev.proinvestor.com/forum/post/7668063Tue, 31 Oct 2023 15:37:05 GMTmanufacturing was halted in 21, then when it came back pend up demand distorted the numbers. But it is not currently as strong as hoped; so that is why i hope Amgen can get a push going again and also get approvals outside of US

]]>https://dev.proinvestor.com/forum/post/7668071https://dev.proinvestor.com/forum/post/7668071Tue, 31 Oct 2023 15:00:37 GMTDe når næppe samme salg som i 22. Måske som i 21.

]]>https://dev.proinvestor.com/forum/post/7668058https://dev.proinvestor.com/forum/post/7668058Tue, 31 Oct 2023 14:51:22 GMTIt would be interesting to know the reason for a decline in sale/prescriptions for Tapezza.

]]>https://dev.proinvestor.com/forum/post/7668057https://dev.proinvestor.com/forum/post/7668057Tue, 31 Oct 2023 14:49:14 GMTSo already a 8% decline yoy?

]]>https://dev.proinvestor.com/forum/post/7668059https://dev.proinvestor.com/forum/post/7668059Tue, 31 Oct 2023 14:46:44 GMThttps://www.fiercepharma.com/pharma/tepezza-sales-still-stagnant-amgen-has-plan-boost-newly-acquired-ted-drug

]]>https://dev.proinvestor.com/forum/post/7668060https://dev.proinvestor.com/forum/post/7668060Tue, 31 Oct 2023 14:38:27 GMTTepezza sales not yet included in the Amgen sales, but discussed in the call Q3 '23 -In the third quarter, sales of Tepezza reached $453 million, the company said on Tuesday. While Amgen was quick to point out that it was a 2% increase from the previous quarter, it also was an 8% decline year over year. Amgen has a plan to get Tepezza’s groove back, using a playbook that the company employed with vasculitis drug Tavneos after its 2020 acquisition of Chemocentryx.

]]>https://dev.proinvestor.com/forum/post/7668056https://dev.proinvestor.com/forum/post/7668056Tue, 31 Oct 2023 14:38:25 GMTSITC23
681- innovaTV 207 Parts E and F: A phase 2 study of tisotumab vedotin in patients with head and neck squamous cell carcinoma (trial in progress) https://jitc.bmj.com/content/11/Suppl_1/772

]]>https://dev.proinvestor.com/forum/post/7668055https://dev.proinvestor.com/forum/post/7668055Tue, 31 Oct 2023 14:24:50 GMTSITC23 Abstract 1181- GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody-CD40x4-1BB), exhibits in vivo antitumor activity and peripheral immune modulation https://jitc.bmj.com/content/11/Suppl_1/1302

]]>https://dev.proinvestor.com/forum/post/7668053https://dev.proinvestor.com/forum/post/7668053Tue, 31 Oct 2023 14:19:18 GMTSITC Abstract 813- Combination of HexaBody-CD27 with PD-(L)1 blockade potentiates single-agent activity leading to enhanced human T-cell effector functions in vitro https://jitc.bmj.com/content/11/Suppl_1/912

]]>https://dev.proinvestor.com/forum/post/7668050https://dev.proinvestor.com/forum/post/7668050Tue, 31 Oct 2023 14:13:57 GMTDet vil jeg nok lige se, før jeg tror det;-)

]]>https://dev.proinvestor.com/forum/post/7668064https://dev.proinvestor.com/forum/post/7668064Tue, 31 Oct 2023 14:05:25 GMTMed udviklingen i det øvrigt marked begynder det at ligne en forløbig bund... så må vi se om vi stiger 15-20% inden fredag

]]>https://dev.proinvestor.com/forum/post/7668066https://dev.proinvestor.com/forum/post/7668066Tue, 31 Oct 2023 13:47:01 GMTDet ser faktisk ikke så tosset ud med 1980 området.... 2 gange i dag, har aktien været i området, og begge gange med en pæn rekyl til følge...

]]>https://dev.proinvestor.com/forum/post/7668054https://dev.proinvestor.com/forum/post/7668054Tue, 31 Oct 2023 13:22:49 GMTHvis man skal have de positive briller på, ser det ud til vi har en bund omkring kurs 1980. Det kan selvsagt ændre sig.

]]>https://dev.proinvestor.com/forum/post/7668052https://dev.proinvestor.com/forum/post/7668052Tue, 31 Oct 2023 12:55:37 GMT